Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients

The recent controversy regarding the use of pill for cycle planning in GnRH antagonists IVF cycle has driven the search for new ways to plan IVF cycles in order to avoid weekends or to equally distribute the workload. Recently, mid-late luteal phase oral estrogens seem to be as good as the pill. The investigators will compare OCP vs oral estrogens to plan the initiation of IVF cycles.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

IVI Madrid

Madrid, 28223, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1st or 2nd IVF cycle
BMI <30 kg/m2
regular menstrual cycles
basal FSH <10IU and E2 <60pg/mL

Exclusion criteria

polycystic ovaries
endometriosis
previous ovarian surgery
previous low ovarian response

Treatment and study plan

Levonorgestrel and ethinylestradiol

Drug

30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days

estradiol valerate

Drug

4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle

Primary outcomes

Implantation rate

Time frame: 20 days after the embryo transfer

number of embryonic sacs visible by ultrasound divided by the number of embryos transferred

Sponsors and collaborators

Lead sponsor

IVI Madrid

Other

Registry information

Important dates

Study start: 2012
Primary completion: 2012
Study completion: 2013
First posted: Dec 29, 2011
Registry last updated: Mar 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed